Archive | Science RSS feed for this section

Autism Science Foundation announces Pre & Post Doctoral Training Fellowships

21 Mar

The Autism Science Foundation has announced their pre-doctoral and post doctoral fellowships for this year. The press release is quoted below.

This is an area of research funding I approve of–supporting new researchers. The more new, good people we can pull into the field, the better off autism research will be in the long term.

Pre & Post Doctoral Training Fellowships Announced

(March 21, 2011-New York, NY)–The Autism Science Foundation, a not-for-profit organization dedicated to funding autism research, today announced the recipients of its annual pre and post doctoral fellowships. In all, $220,000 in grants will be awarded to student/mentor teams conducting research in autism interventions, early diagnosis, biomarkers, and animal models. This funding level represents a 22% increase over last year’s training fellowship grants.

“We are thrilled to be increasing our funding in only our second year of operations, and to be supporting such high quality grants”, said Autism Science Foundation co-founder Karen London. “Outstanding research is the greatest gift we can offer our families. We are so grateful to all our donors and volunteers who have come together to support autism research.”

The following new projects have been selected for funding:

Post Doctoral Fellowships:

* Jill Locke/David Mandell: University of Pennsylvania
Implementing Evidence-Based Social Skills Interventions in Public School Settings
* Portia McCoy/Ben Philpot: University of North Carolina
Ube3a Requirements for Structural Plasticity of Synapses
* Haley Speed/Craig Powell: UT Southwestern University
Identifying Impairments in Synaptic Connectivity in Mouse Models of ASD
* Elena Tenenbaum/Stephen Sheinkopf: Women & Infants Hospital andBrown University
Attentional Distribution and Word Learning in Children with Autism

Pre-Doctoral Fellowships:

* Jessica Bradshaw/Robert Koegel: University of California at Santa Barbara
Prelinguistic Symptoms of Autism Spectrum Disorders in Infancy
* Christie Buchovecky/Monica Justice: Baylor College of Medicine
Identifying Genetic Modifiers of Rett Syndrome in the Mouse

Read more about these studies.

The Autism Science Foundation is a 501(c)3 public charity that provides funding to scientists and organizations conducting autism research. ASF also provides information about autism to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism. Learn more at http://www.autismsciencefoundation.org

disclaimer–I have accepted support from ASF to attend IMFAR 2011./

Proton Magnetic Resonance Spectroscopy and MRI Reveal No Evidence for Brain Mitochondrial Dysfunction in Children with Autism Spectrum Disorder.

16 Mar

A study published today looks for mitochondrial dysfunction in autistic children. In specific, the researchers are looking directly at the brains of autistic children. The team, from the University of Washington, used both MRI (Magnetic Resonance Imaging) and proton magnetic resonance spectroscropic imaging (HRMS). MRI gives structural information on soft tissues. HMRS is a “spectroscopic” techinque: it gives chemical information on
Here’s a good reference with a discussion of HMRS on brain tissue (as a spectroscopy, not an imaging technique): Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy

With that background in hand, here is the abstract from the recent study on autism:

Proton Magnetic Resonance Spectroscopy and MRI Reveal No Evidence for Brain Mitochondrial Dysfunction in Children with Autism Spectrum Disorder.

Corrigan NM, Shaw DW, Richards TL, Estes AM, Friedman SD, Petropoulos H, Artru AA, Dager SR.

Department of Radiology, University of Washington, Seattle, WA, USA.
Abstract

Brain mitochondrial dysfunction has been proposed as an etiologic factor in autism spectrum disorder (ASD). Proton magnetic resonance spectroscopic imaging ((1)HMRS) and MRI were used to assess for evidence of brain mitochondrial dysfunction in longitudinal samples of children with ASD or developmental delay (DD), and cross-sectionally in typically developing (TD) children at 3-4, 6-7 and 9-10 years-of-age. A total of 239 studies from 130 unique participants (54ASD, 22DD, 54TD) were acquired. (1)HMRS and MRI revealed no evidence for brain mitochondrial dysfunction in the children with ASD. Findings do not support a substantive role for brain mitochondrial abnormalities in the etiology or symptom expression of ASD, nor the widespread use of hyperbaric oxygen treatment that has been advocated on the basis of this proposed relationship.

Does this mean that mitochondrial dysfunction never occurs in autistics? No. But it makes it very unlikely that more than a fraction of autistics have mitochondrial dysfunction in their brains.

Beyond that, the use of spectroscopic imaging is very impressive to me. MRI structural data is quite valuable on its own, but adding chemical information is very powerful.

Reauthorizing the Combating Autism Act?

12 Mar

The Combating Autism Act (CAA) committed the US government to fund autism research. As part of this effort, the Interagency Autism Coordinating Committee (IACC) was re-authorized (it actually predated the CAA, having been established under the Children’s Health Act of 2000)

At the end of the last congress, a Combating Autism Reauthorization Act (CARA) was presented. It was a nice move by Sentator Dodd as he was retiring, but as you will read if you follow the link, that bill is dead:

This bill never became law. This bill was proposed in a previous session of Congress. Sessions of Congress last two years, and at the end of each session all proposed bills and resolutions that haven’t passed are cleared from the books. Members often reintroduce bills that did not come up for debate under a new number in the next session.

If you go to the Senate’s webpage and enter “autism” as a search term for current bills, you will get two. Neither is the re-authorization of the CAA. Similar results come from searching Thomas for autism.

Sometimes I think, I just can’t find it. But it really isn’t there. In their piece Urge Congress to Reintroduce the Combating Autism Reauthorization Act!, “The Child Health Site” is asking people to sign a petition to reintroduce CARA.

The text of the original CAA you will find the following (or similar) a number of times: Sunset.–This section shall not apply after September 30, 2011.

Authorization for funding will sunset this year. The IACC will sunset this year. That is, of course, unless a re-authorization occurs. I haven’t seen much from the national autism organizations calling for action on this. There is undoubtedly much going on behind the scenes, but it strikes this observer that perhaps something should have happened by now.

Funding Science in a Time of Austerity

12 Mar

Funding Science in a Time of Austerity is a blog post by Tom Insel, director of the National Institute of Mental Health (NIMH) in the US.

I’ve discussed many news stories of late which discuss special education in these tight fiscal times. Naturally research will be impacted as well. While the article by Tom Insel does not discuss autism specifically, it is worth a read. NIMH has not had a final appropriation from the government for this fiscal year (which started in Oct. 2010). And they are expecting cuts for fiscal year 2012.

Following is a post by Tom Insel, director of the NIMH:

C. S. Lewis once said that the “task of a modern educator is not to cut down jungles but to irrigate deserts.” The same might be said of an NIH institute today. But our ability to irrigate deserts may be compromised as we appear to be facing an austere funding future. As the Nation struggles to regain its economic footing, the final budgets for NIH in 2011 and 2012 remain uncertain. But there is little doubt that these will be tough years for NIMH funding.

Here is a quick synopsis. Following the doubling of the NIH budget from 1998-2003, NIMH has received budgets with sub-inflationary increases each year. By 2009, we had lost about 18 percent of our purchasing power relative to 2003, but through strategic cuts in awards, reductions in the out-years of multi-year grants, and elimination of programs, NIMH was able to maintain relatively stable funding throughout this period. By stable funding, I mean that we continued to support roughly 550 new research grants (R01 and R21-type grants) each year, representing at least 15 percent of proposals.

In 2009 and 2010, the American Recovery and Reinvestment Act (ARRA) brought a surge in funding to create jobs. With over $370M, NIMH was able to support several innovative projects, create or retain jobs, and fund some additional R01-type grants (for 2 years) on top of our regular appropriated budget. But this one-time surge from ARRA obscured the longer-term pattern of flat budgets that continued in 2009 and 2010 beneath the ARRA bubble. In 2010, the NIMH budget was 2.6 percent higher than 2009, still losing ground to inflation.

What about 2011? Although our budget year began October 1, 2010, we are still awaiting a final appropriation. Last week, Congress passed a continuing resolution until March 18, which means we will continue to operate under our 2010 budget rather than the President’s 2011 budget proposed last February. Prior to March 18th, Congress must vote either to extend the continuing resolution or to appropriate a budget for the remainder of the year. Both houses of Congress are concerned about the growing deficit and are committed to reining in spending, especially within the 12 percent of the budget labeled as “discretionary.” This will almost certainly mean a reduction in the NIH and NIMH budgets, but we do not know the extent of this reduction. The House voted for a $1.6B reduction below the 2010 NIH budget for 2011, including a 4.1 percent reduction (-$60M from 2010) for NIMH, but this budget still needs to be considered by the Senate.

In the absence of a final budget for this year and with expectations that we will likely see reductions in 2012, NIMH has been cautious about funding grants. We have a few principles that have guided us: prioritize research relevant to our strategic plan, support innovation, maximize the number of R01 grants, and protect early stage scientists. In support of these principles, we have reduced our intramural program, funded fewer centers, and reduced support of some large programs.

But even with these changes, the 2010 budget leaves us short in 2011. Partly because of the number of continuing grants and partly because of the increasing average cost of new awards, if we receive the full 2010 budget for 2011, we are projecting 481 new grants, representing roughly 10 percent of proposals. This would be the first time since 1999 that we would fund fewer than 500 new grants and would mark the lowest success rate in over 15 years. If the 2011 appropriation is 4.1 percent less than the 2010 budget, the actual number of new grants funded will likely be below 400.

Not surprisingly, this situation is creating anxiety in the scientific community. Basic scientists believe that the money has been shifted to translation. Clinical researchers say that funds are only going to basic science. But in fact, the Division of Neuroscience and Basic Behavioral Science, which was 27 percent of the total NIMH budget in 2005, was 29 percent in 2010 and will likely be close to this portion again in 2011.

Some have suggested that the funds are going to Centers or the intramural program instead of investigator-initiated R01 grants. But the percentage of R01s has only increased over the past decade.

A few scientists have suggested that the problem is a recent change in the review policy, allowing only a single re-submission. While this policy must seem catastrophic for someone who just missed the payline with a re-submitted grant, re-instating the “A2” would only delay funding for those within the payline. It may not increase the number of grants funded or the success rate.

For scientists, this may feel like a funding desert. During this relative drought, there may be many reasons for complaints. But the bottom line is that funds for new grants are the lowest we have seen in several years and the average costs of new grants is higher than ever ($419K in 2010 vs $313K in 2005). NIMH is committed to funding the highest impact science with the available funds. But as much as we would like to “irrigate the desert,” some outstanding science will, unfortunately, not get funded. And those projects selected for funding may receive less than optimal support.

What makes this desert especially difficult is that the scientific opportunities have never been better. We have unprecedented traction in the science necessary to make progress for helping people with mental illness. However, in this period of austerity, we will not at this time be able to fund some of the science that will make a difference for those in greatest need.

Mitochondrial Disease and Autism: Linked?

11 Mar

Mitochondrial disease and autism. I don’t read about it as much as during the peak of the Hannah Poling story, but it is a big topic. Emily Willingham at
Thinking Person’s Guide to Autism has put together an excellent post on the subject. Here’s the first paragraph:

Hannah Poling’s family entered the national spotlight when they revealed that Hannah’s autism-like symptoms may have been linked to a reaction to several childhood vaccines at once in combination with her mitochondrial dysfunction. Her case was not the first revelation of a possible mitochondrial disorder (MD)-autism spectrum disorder (ASD) link, but because of her ultimately successful vaccine injury suit, she became the avatar of the vaccines-cause-harm movement — which almost eclipsed the real scientific and therapeutic feature of her case: the mitochondria.

I’d love to do a wholesale copy of the post, but that’s hardly fair now, is it? So, I’ll send you all to the Thinking Person’s Guide to Autism and Mitochondrial Disease and Autism: Linked?

Vaccinated Children Not at Higher Risk of Infections or Allergic Diseases, Study Suggests

10 Mar

Seems German science has asked and answered the question everyone who believes vaccines damage the immune system wanted answering:

Do vaccinations put too much strain on or weaken children’s immune systems? Roma Schmitz and her colleagues from the Robert Koch Institute investigate exactly this research question in the current issue of Deutsches Ärzteblatt International.

Their data are based on the results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).

In their study, the authors compare the occurrence of infections and allergies in vaccinated and unvaccinated children and adolescents. These include bronchitis, eczema, colds, and gastrointestinal infections.

The evaluation showed that unvaccinated children and adolescents differ from their vaccinated peers merely in terms of the frequency of vaccine preventable diseases. These include pertussis, mumps, or measles. As expected, the risk of contracting these diseases is substantially lower in vaccinated children and adolescents.

Autism Science Foundation announces IMFAR stakeholder travel grant recipients

10 Mar

The Autism Science Foundation has announced the recipients of this year’s stakeholder travel grants for IMFAR.

The press release is below:

AUTISM SCIENCE FOUNDATION ANNOUNCES
IMFAR STAKEHOLDER TRAVEL GRANT RECIPIENTS

IMFAR Stakeholder Travel Awards will Support Parents, Individuals with Autism, Teachers & Students

(March 10, 2011—New York, NY)–The Autism Science Foundation, a not for profit organization dedicated to supporting and funding autism research, today announced the recipients of its IMFAR Stakeholder Travel grants. ASF will make 11 awards of up to $1000 to be used to cover expenses related to attending the International Meeting for Autism Research in San Diego in May 2011. After the conference, grant recipients will be expected to share what they’ve learned with families in their local communities and/or online.

This year’s recipients are:

Geraldine Bliss–Parent
Matthew Carey–Parent
Shannon Des Roches Rosa–Parent
Mark Fornefeld–Self Identified Individual with Autism
Abby Hare–Graduate Student
Erin Lopes–Parent
Molly McGrath–Self Identified Individual with Autism/MIT Media Lab
Brianna Miller–Special Ed Teacher, Newark Public Schools
Sharman Ober-Reynolds–Parent/Senior Research Coordinator, SARRC
Megan O’Boyle –Parent
Max Rolison–Undergraduate Student

IMFAR is an annual scientific meeting, convened each spring, to promote exchange and dissemination of the latest scientific findings in autism research and to stimulate research progress in understanding the nature, causes, and treatments for autism spectrum disorders. IMFAR is the annual meeting of the International Society for Autism Research (INSAR).

“We are thrilled to be able to give back directly to the autism community in a research-focused way”, said Alison Singer, President of the Autism Science Foundation. “We are confident that the award recipients will all do a great job of bringing critical new research information to their communities, improving the speed with which the latest data are shared with the broader autism community.”

The Autism Science Foundation is a 501(c)(3) public charity launched in 2009 whose mission is to support autism research by providing funding to those who conduct, facilitate, publicize and disseminate autism research. ASF also provides information about autism to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism.

The International Society for Autism Research (INSAR) is a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders. INSAR was created in 2001. The society runs the annual scientific meeting – the International Meeting for Autism Research (IMFAR) and publishes the research journal “Autism Research”.

Contact Info:

Julie Martin
Events and Media Manager
Autism Science Foundation
jmartin@autismsciencefoundation.org
419 Lafayette Street, 2nd floor
New York, NY 10003

Lack of Infection with XMRV or Other MLV-Related Viruses in Blood, Post-Mortem Brains and Paternal Gametes of Autistic Individuals.

7 Mar

Another paper has come out showing no link between XMRV (Xenotropic murine leukemia virus-related virus) and autism. A study last year (discussed on LBRB here) stated “These results imply that XMRV is not associated with autism.” In a study just released in the journal PLOS One, we see more evidence against such a link:

Lack of Infection with XMRV or Other MLV-Related Viruses in Blood, Post-Mortem Brains and Paternal Gametes of Autistic Individuals.

Lintas C, Guidi F, Manzi B, Mancini A, Curatolo P, Persico AM.

Laboratory of Molecular Psychiatry and Neurogenetics, University Campus Bio-Medico, Rome, Italy.
Abstract

BACKGROUND: Autistic spectrum disorder (ASD) is characterized by impaired language, communication and social skills, as well as by repetitive and stereotypic patterns of behavior. Many autistic subjects display a dysregulation of the immune system which is compatible with an unresolved viral infection with prenatal onset, potentially due to vertical viral transmission. Recently, the xenotropic murine leukemia virus-related virus (XMRV) has been implicated in chronic fatigue syndrome (CFS) and in prostate cancer by several, though not all studies.

METHODOLOGY/PRINCIPAL FINDINGS: We assessed whether XMRV or other murine leukemia virus (MLV)-related viruses are involved in autistic disorder. Using nested PCR targeted to gag genomic sequences, we screened DNA samples from: (i) peripheral blood of 102 ASD patients and 97 controls, (ii) post-mortem brain samples of 20 ASD patients and 17 sex- and age-matched controls, (iii) semen samples of 11 fathers of ASD children, 25 infertile individuals and 7 fertile controls. No XMRV gag DNA sequences were detected, whereas peripheral blood samples of 3/97 (3.1%) controls were positive for MLV. CONCLUSIONS|

SIGNIFICANCE: No MLV-related virus was detected in blood, brain, and semen samples of ASD patients or fathers. Hence infection with XMRV or other MLV-related viruses is unlikely to contribute to autism pathogenesis.

The study concludes quite simply:

Our results, combined with those reported by Sutherfield et al [14], render XMRV contributions to autism highly unlikely. Nonetheless we cannot exclude that MLV-related viruses may play a role in rare cases.

Note that “Sutherfield” is a typo. Should be Satterfield. The reference is to the paper in Molecular Autism which was the topic of the discussion from last year that I linked to in the introduction to this piece.

Jaundice as a cause of autism? Probably not.

4 Mar

A few months back an article appeared in the journal Pediatrics: Neonatal Jaundice, Autism, and Other Disorders of Psychological Development. It’s one of those articles I meant to blog and just never got around to.

Here’s the abstract:

Objectives The goals were to study the association between neonatal jaundice and disorders of psychological development in a national, population-based cohort and to study whether gestational age, parity, and season of birth influenced that association.

Methods A population-based, follow-up study of all children born alive in Denmark between 1994 and 2004 (N = 733 826) was performed, with data collected from 4 national registers. Survival analysis was used to calculate hazard ratios (HRs).

Results Exposure to jaundice in neonates was associated with increased risk of disorders of psychological development for children born at term. The excess risk of developing a disorder in the spectrum of psychological development disorders after exposure to jaundice as a neonate was between 56% (HR: 1.56 [95% confidence interval [CI]: 1.05–2.30]) and 88% (HR: 1.88 [95% CI: 1.17–3.02]). The excess risk of infantile autism was 67% (HR: 1.67 [95% CI: 1.03–2.71]). This risk for infantile autism was higher if the child was conceived by a parous woman (HR: 2.71 [95% CI: 1.57–4.66]) or was born between October and March (HR: 2.21 [95% CI: 1.24–3.94]). The risk for infantile autism disappeared if the child was conceived by a primiparous woman (HR: 0.58 [95% CI: 0.18–1.83]) or was born between April and September (HR: 1.02 [95% CI: 0.41–2.50]). Similar risk patterns were found for the whole spectrum of autistic disorders.

Conclusions Neonatal jaundice in children born at term is associated with disorders of psychological development. Parity and season of birth seem to play important roles.

This week, three response letters were published in Pediatrics. These originally appeared as online letters:

Effects of perinatal asphyxia plus bilirubin?

Jaundice-Autism Link Unconvincing

and

neonatal jaundice: should we go crazy?

The first article (Effects of perinatal asphyxia plus bilirubin) was supportive, ending with:

Thank you for publishing the report by Maimberg et al., which will hopefully help direct research on perinatal brain vulnerability as an important area of investigation

The second article, as you might guess, was not. “Jaundice-Autism Link Unconvincing”. This was written by Thomas B Newman and Lisa Croen. Lisa Croen has previously published on biliruben (the substance which causes jaundice). They present a number of confounders which should be considered. They also note the potential problems with an incomplete study:

Raising concerns about the danger of jaundice could lead parents or clinicians to treat jaundice more aggressively. However, the Danish study also lacks any information on phototherapy. Thus, if the association is real, it could be due to phototherapy, rather than to the jaundice itself, in which case frightening families about jaundice could lead to an increase in treatment, which would be particularly counter-productive.

The third response notes “In this regard, it should be quoted the paper by Croen at al, who studied neonatal bilirubin levels (although the presence of haemolytic diseases was unspecified) in relation with autism spectrum disorders and did not find any association”. Yes, that’s the same Croen as in the second response. There was no association in those data and that previous study.

Another online letter is even more direct: Neonatal Jaundice Does Not Cause Autism.

In the Response from authors, we see that the authors have performed a reanalysis:

Sir, it has come to our attention that table 3 in our paper (1) only includes patients treated in somatic Danish hospitals identified in the Danish National Hospital Register. If we also add the patients diagnosed with autism spectrum disorders (ASD) at the mental hospitals only (n=6171), the revised figures will look like this:

Association between neonatal jaundice and autism spectrum disorders (F84.0-F84.9):

All;

Crude HR=1.29, adjusted HR=1.07 (0.94-1.21)

Term=>37 weeks;

Crude HR=1.23, adjusted HR=1.06 (0.90-1.25)

Preterm< 37 weeks;

Crude HR=1.17,adjusted HR=1.05 (0.83-1.32)
As seen in the new analysis (including children from the mental hospital only)the association between jaundice and autism is substantially attenuated after adjustments which make us doubt the causal nature of our observation. If the association is causal it apparently only involves the more severe cases reaching the somatic hospital. Our findings are in line with what has been reported from Sweden (2) using a similar case mix. It is likely that our study and the Swedish study are confounded by co- morbidity.

“which make us doubt the causal nature of our observation.”.

I’m rather glad I didn’t blog this at the time. This looks like the science community working to self-correct itself.

IMFAR Conference 2011

2 Mar

IMFAR, the International Meeting for Autism Research, is held every year. It is presented by INSAR, the International Society for Autism Research. IMFAR is the largest autism conference held, with hundreds of presentations of new research results.

IMFAR 2011 will be held in San Diego, California, May 12-14, at the Manchester Grand Hyatt.

The program is not out yet, as they are still working on culling the over 1,000 abstracts submitted:

IMFAR 2011 Programming is Underway
Over 1,000 abstracts were submitted this year for IMFAR 2011. The Program Committee is currently reviewing abstracts and panel submissions. Abstract acceptance notifications are scheduled to be sent via e-mail by March 4

Keynote speakers have been announced:

Eric Courchesne, Ph.D

Eric Courchesne is Professor of Neurosciences in the School of Medicine at the University of California San Diego (UCSD) and Director of the NIH-funded UCSD Autism Center of Excellence. He is an internationally recognized expert on brain structural and functional abnormalities associated with autism. His Autism Center of Excellence aims to identify biobehavior markers of autism that will allow for earlier diagnosis and treatment by integrating behavioral, developmental, genetic, neuroanatomic and neurofunctional findings. Current ACE Center research includes MRI studies have identified structures that are abnormal at infancy in autism and elucidated patterns of abnormal growth from infancy through adulthood. Current functional brain imaging techniques seek to establish links between autistic symptoms in infants and toddlers and the brain sites responsible for them. Studies of brain tissue have discovered novel gene expression profiles and cellular defects in the frontal cortex at the youngest ages in autism and have additionally characterized how these abnormalities change with age from early childhood and to adulthood. Dr. Courchesne’s studies have resulted in over 180 publications with an overall very high impact factor as determined by the ISI Web of Knowledge. His research has been published in Science, JAMA, Lancet and the New England Journal of Medicine and is supported through grants from NIMH, NINDS, NICHD, the Simons Foundation and Autism Speaks.

Ricardo Dolmetsch Ph.D.

Dr. Ricardo Dolmetsch is a faculty member in the Department of Neurobiology at Stanford University where he directs a laboratory that studies the underlying cellular and molecular basis of autism spectrum disorders (ASDs). He is a graduate of Brown University, received his graduate degree from Stanford and did his postdoctoral training at Harvard Medical School. His group has pioneered the use of adult stem cells to study the development of the brain and the mechanisms that lead to neurodevelopmental disease. He has received numerous awards for his work including the Society for Neuroscience Young Investigator Award in 2007 and the NIH Director’s Pioneer Award in 2008. He is the author of more than 30 scholarly publications and is the parent of a child with ASD.

Professor Annette Dionne Karmiloff-Smith

Annette Karmiloff-Smith was until 2003 Head of the Neurocognitive Development Unit at the Institute of Child Health in London where she ran a research team studying typical/atypical development and genotype/phenotype relations. She now occupies a Professorial Research Fellowship at the Birkbeck Centre for Brain and Cognitive Development, University of London. She has a “Doctorat en Psychologie Génétique et Expérimentale” from the University of Geneva, where she studied with the famous Swiss psychologist, Jean Piaget. She is the author of 7 books and of over 200 chapters and articles in scientific journals, as well as a series of booklets for parents on different aspects of foetal, infant and child development. Her research on neurodevelopmental syndromes focuses on identifying basic-level deficits in early infancy and their cascading effects over developmental time on the resulting cognitive phenotype.

All are excellent, but one stands out in my mind, just because I’ve read a lot of his work–
Eric Courchesne is one of the most published and most cited researchers in autism. He’s been working on brain structure (and other topics) for 20 years (earliest publication I see is from 1978). For publication geeks out there, his H-index is at least 59 (based on a quick search of his papers). For the 99.99% of people (or more) who have never heard of the H-index, I’ll just say, his publication record is damned impressive.

IMFAR is not cheap, at $475 for “early bird membership” for non-members. There is no reason to attend as a non-member. The price for a membership in INSAR is $100, and the conference fee for a member is $100 less than the non-member price.

IMFAR is a busy, scientific conference. Most talks are 15 minutes, including questions. This doesn’t leave much time for the speaker to give background information. Poster sessions will be large–many, many posters being shown at the same time. But just take a look at past conference programs. The amount of work presented is amazing.

I am waiting eagerly for the program to be announced. There is also a flurry of press releases during the conferences as the embargoes are lifted on research projects presented there. Yes, I get excited by new research and IMFAR is pretty much the most concentrated announcement of new research in the autism world each year.